Wrist Nerve Block as a New Treatment in Patients With Rheumatoid Arthritis (RA: rheumatoid)

September 6, 2026 updated by: Yousra Aly Lamie, Sohag University

The Role of Wrist Nerve Block as a Therapeutic Modality in Patients With Rheumatoid Arthritis

Rheumatoid arthritis is a chronic, systemic, autoimmune inflammatory disease that mainly affects the joints and periarticular soft tissues.[1]

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

180

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Ahmed mahrous elsamman
  • Phone Number: 00201122040682

Study Locations

  • Egypt
      • Sohag, Egypt
        • Sohag University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. RA patients fulfilled the 2010 American College of Rheumatoid Arthritis classification criteria.[8]
  2. Oligoarticular RA patients including wrist joint.
  3. Age above 18 years old.
  4. Patient cooperative and can answer questions.

Exclusion Criteria:

  1. Other rheumatologic or collagen diseases.
  2. Age below 18 years.
  3. Patients who underwent concomitant procedures to address underlying pathology such as radial styloidectomy, ulna shortening, fracture fixation, arthroplasty, arthrodesis, and ligament reconstructions.
  4. Patients who suffered from hand deformities or limitation.
  5. Uncooperative patients.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Group 3
Active Comparator: Group 1
wrist nerve block
Procedure: Wrist local steroid injection
Wrist nerve block by injection is a diagnostic or therapeutic procedure used to treat chronic wrist pain, typically arising from arthritis or instability, by interrupting sensory nerve signals (mainly PIN/AIN nerves) with an anesthetic or neurolytic agent. This less-invasive approach provides pain relief, often serving as a predictor for success before permanent surgical denervation.[4]
Placebo Comparator: Group 2
wrist local steroid injection
Procedure: Wrist local steroid injection
Wrist nerve block by injection is a diagnostic or therapeutic procedure used to treat chronic wrist pain, typically arising from arthritis or instability, by interrupting sensory nerve signals (mainly PIN/AIN nerves) with an anesthetic or neurolytic agent. This less-invasive approach provides pain relief, often serving as a predictor for success before permanent surgical denervation.[4]

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in wrist pain severity measured by the Visual Analogue Scale (VAS) from baseline to Week 16
Time Frame: Baseline to Week 16

Change in wrist pain severity measured using the Visual Analogue Scale (VAS) from baseline to Week 16 Visual Analogue Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.

Wrist pain severity will be assessed using the Visual Analogue Scale (VAS), ranging from 0 to 10, where 0 represents no pain and 10 represents the worst imaginable pain. Higher scores indicate greater pain. The change in VAS score from baseline to Week 16 will be assessed.
Baseline to Week 16
Assessment of wrist pain improvement
Time Frame: 16 weeks
• Change in wrist pain severity measured by the Visual Analogue Scale (VAS) from baseline to Week 16
16 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

August 15, 2026

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

July 1, 2027

Study Registration Dates

First Submitted

August 30, 2026

First Submitted That Met QC Criteria

September 6, 2026

First Posted (Actual)

September 11, 2026

Study Record Updates

Last Update Posted (Actual)

September 11, 2026

Last Update Submitted That Met QC Criteria

September 6, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Soh-Med-26-7-26MS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe